Clinicians’ adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness

Mirko Manchia1,2*, Giorgio Firinu1, Bernardo Carpiniello1 and Federica Pinna1

Abstract

Background: Severe mental illness (SMI) has considerable excess morbidity and mortality, a proportion of which is explained by cardiovascular diseases, caused in part by antipsychotic (AP) induced QT-related arrhythmias and sudden death by Torsade de Point (TdP). The implementation of evidence-based recommendations for cardiac function monitoring might reduce the incidence of these AP-related adverse events. To investigate clinicians’ adherence to cardiac function monitoring before and after starting AP, we performed a retrospective assessment of 434 AP-treated SMI patients longitudinally followed-up for 5 years at an academic community mental health center.

Methods: We classified antipsychotics according to their risk of inducing QT-related arrhythmias and TdP (Center for Research on Therapeutics, University of Arizona). We used univariate tests and multinomial or binary logistic regression model for data analysis.

Results: Univariate and multinomial regression analysis showed that psychiatrists were more likely to perform pre-treatment electrocardiogram (ECG) and electrolyte testing with AP carrying higher cardiovascular risk, but not on the basis of AP pharmacological class. Univariate and binomial regression analysis showed that cardiac function parameters (ECG and electrolyte balance) were more frequently monitored during treatment with second generation AP than with first generation AP.

Conclusions: Our data show the presence of weaknesses in the cardiac function monitoring of AP-treated SMI patients, and might guide future interventions to tackle them.

Keywords: Torsade de point, Electrolytes, ECG, Excess mortality, Side effects

Background

Severe mental illness (SMI), including schizophrenia (SCZ), bipolar disorder (BD), major depressive disorder (MDD) and personality disorders (PD), has considerable excess morbidity and mortality [1–3], resulting in a substantially reduced (10-20 years) life expectancy compared to the general population [3, 4]. Indeed, individuals with SMI are susceptible to the development of physical health problems [2]. This high liability appears to be determined by several socioeconomic and clinical [2, 5], treatment-related [6], and genetic [7] factors. For instance, low income, absence of health insurance, and number of concomitant medical conditions seem to explain a large proportion of the excess mortality found in SMI patients [5]. Moreover, a number of severe medical conditions such as nutritional and metabolic diseases, cardiovascular diseases, viral diseases, respiratory tract diseases, musculoskeletal diseases, sexual dysfunction, pregnancy complications, stomatognathic diseases, and possibly obesity-related cancer are more prevalent in SMI patients compared to unaffected
individuals [2]. It is possible that these epidemiological findings could be explained, at least in part, by the use of psychotrophic treatments, particularly antipsychotics (AP), in SMI patients [6]. Of note, adverse effects on physical health appear to be greatest at higher dosages of AP, when polypharmacy is present, and when vulnerable populations (e.g., old or young) are treated [6]. Finally, individuals with SMI might carry frameworks of genetic susceptibilities that make them more prone to the development of somatic illnesses than the general population (i.e., shared genetic susceptibilities) [7]. These hypotheses are supported by the evidence that higher rates of comorbid somatic illnesses, such as diabetes mellitus type 1 or type 2, were observed in SMI patients in the prepharmacological era [8, 9], and that genetic risk variants for somatic conditions confer also risk for SMI [7, 10].

Another key factor contributing to the excess mortality observed in SMI patients is the presence of obstacles to the implementation of accurate screening and assessment procedures for physical health aspects in SMI patients [11]. It has been proposed that specific strategies, such as screening the patient’s personal and family history at baseline to identify high-risk individuals and to ensure early detection of changes in critical parameters, as well as the adoption of ongoing surveillance methods, might help in setting up adequate standards of care for SMI patients [11]. The implementation of a specific monitoring algorithm is crucial in SMI patients, since the vast majority of them undergo treatment with first and second generation AP, which have specific safety profile issues impacting on cardiovascular, metabolic and endocrine function of treated patients [12]. Concerning cardiovascular function, there is substantial evidence pointing to a relationship between AP treatment and prolongation of QT interval [12, 13]. The frequency of QTc-related arrhythmias in AP-treated psychiatric patients has been estimated at 8%, leading to a rate of sudden unexpected death twice that observed in normal populations and corresponding to 10-15 deaths per 10,000 person-year of observation [14]. Of note, the risk for QTc prolongation and related arrhythmias, such as Torsade de Point (TdP), is substantially increased in the presence of electrolytes imbalance, individual history of syncope, a family history of sudden cardiac death at an early age, congenital QT syndrome, and/or known heart disease [11]. First generation AP, such as haloperidol, thioridazine, sertindole, pimozide, droperidol, as well as second generation AP, such as quetiapine, risperidone, olanzapine, iloperidone, ziprasidone, and amisulpride determine QT prolongation in treated patients [13, 15]. Although the molecular mechanisms linking AP to QT prolongation have not been fully elucidated yet, there is evidence pointing to a direct effect on certain subtypes of myocardial ion channels, particularly the human ether-a-go-go-related gene (HERG) that encodes for a protein associated with a cardiac K+ channel involved in regulating repolarizing currents [15–17].

Taken together, this evidence shows that a proportion of the high morbidity and mortality of SMI patients is explained by the presence of cardiovascular conditions, partly caused by the use of AP treatment that can determine QT related arrhythmias and sudden death by TdP. In addition, the lack of appropriate monitoring increases the risk that these events might present as a consequence of, for instance, concomitant electrolytes alterations. The latter parameters are easy to identify, and amenable to treatment, provided that appropriate longitudinal monitoring is set up. In this context, we sought to investigate whether the daily clinical practice routine of psychiatrists is guided by the evidence based recommendations [18–20] on cardiac function monitoring in AP-treated SMI patient and of baseline assessment for the presence of cardiovascular risk factors.

Our primary aim was to investigate the clinicians’ adherence to evidence-based recommendations for cardiac function monitoring, including ECG, biochemical testing (electrolytes), and assessment of individual cardiologic risk factor before and after starting AP treatment in real life clinical setting, as well as for the prescription of psychotrophic drugs at low risk for QT prolongation when indicated. The secondary aims of this study were to assess whether the presence of risk factors for QT-related arrhythmias and TdP, such as cardiac or vascular comorbidities, in AP-treated patients impacted on 1) the choice of AP, or other psychotropic treatment such as antidepressants or mood stabilizers, with low risk for QT prolongation, and 2) on the choice of a specific AP pharmacological class (i.e. first generation versus second generation AP). To this end, we performed a retrospective assessment of 434 AP-treated SMI patients longitudinally followed-up at an academic community mental health center.

**Methods**

**Patient sample**

We conducted a retrospective assessment of 434 SMI patients followed up longitudinally at the Section of Psychiatry of the Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy. All patients gave written and verbal consent to allow reanalysis of clinical data for research purposes. We collected detailed clinical data for the reference period starting on 1 January 2010 and ending on 30 April 2015. Patients were included in the study if: 1) they had a diagnosis of psychotic disorder, mood disorder, or PD according to Diagnostic Statistical Manual (DSM)-IV-TR criteria [21], and 2) treatment with AP (either first or
second generation) was started during the reference period. No exclusion criteria were applied.

**Data extraction protocol**

Longitudinal data on the AP treatment used during the reference period, both as monotherapy and combinatorial AP treatment, were extracted for each patient. As a substantial proportion of the sample changed AP therapy over the reference period, multiple longitudinal treatment data were present for each patient. We also extracted data concerning the combinatorial treatment of AP with other psychotropic drugs that increased the risk of QT-related arrhythmias and TdP.

We performed a systematic chart review of the patients observed at our community health center during the reference period. A description of the selection process of clinical records and data analysis is detailed in Fig. 1. The following demographic, clinical and treatment variables were collected and coded as dummy variables whenever appropriate: 1) gender, 2) date of birth, 3) age, 4) marital status, 5) education, 6) employment, 7) age class (< 20 years, between 21 and 30 years, between 31 and 40, > 40 years), 8) age at onset, 9) main psychiatric diagnosis (psychotic disorder, mood disorder, PD), 10) secondary psychiatric diagnosis according to DSM-IV-TR [21] (anxiety disorder, PD, mood disorders, substance abuse or dependence disorder, somatoform disorders, eating disorders, other psychiatric disorders such as dementia, mental retardation, impulse control disorders, autism), 11) presence/absence of comorbid somatic illnesses as described in Table 1, 12) illness duration (dichotomized on the basis of the median value of illness duration after assessing the distributional properties of illness duration: ≤ 3 years or >3 years), 13) AP treatment (active agent), 14) AP risk category for TdP, 15) pharmacological class of AP (first-versus second-generation AP), 16) presence/absence of baseline ECG testing (before AP treatment), 17) presence/absence of personal history of pre-existing cardiac disease, including heart failure, myocardial infarction, cardiac arrhythmias, and myocarditis, 18) presence/absence of positive familial history of cardiac disease, 19) lifetime assumption of pharmacological treatments determining QT prolongation, 20) use of pharmacological treatments determining QT prolongation during AP therapy, 21) presence/absence of electrolytes levels before AP treatment and frequency of testing, 22) presence/absence of electrolytes levels during AP treatment and frequency of testing, 23) presence/absence of ECG testing during AP treatment and frequency of testing. Furthermore, we created the new categorical variable “Number of cardiac function parameters tested” from the sum of the following dummy variables: presence/absence of baseline ECG testing (before AP treatment), presence/absence of ECG testing during AP treatment, presence/absence of electrolytes levels before AP treatment, presence/absence of electrolytes levels during AP treatment, and presence/absence of personal history of pre-existing cardiac disease, including heart failure, myocardial infarction, cardiac arrhythmias, and myocarditis.

Data were extracted by one author (G.F.) and subsequently verified with senior investigators (F.P., B.C.). Disagreements in extraction and interpretation of data were resolved with consensus-based discussion.

**Torsade de point risk category of psychotropic drugs**

We classified AP according to their risk of inducing QT-related arrhythmias and TdP using the database developed and maintained at the Center for Research on Therapeutics University of Arizona (last access: 2 July 2015) [19]. Briefly, AP and other psychotropic treatments were categorized in 3 classes of risk: A) drugs with known risk of inducing TdP, B) drugs with
possible risk of inducing TdP, and C) drugs with conditional risk of TdP. Drugs in class A have substantial evidence supporting their role in determining QT interval prolongation and are clearly associated with a risk of TdP, even when taken as directed in official labeling. Drugs in class B have substantial evidence supporting their role in determining QT interval prolongation but there is insufficient evidence at this time that these drugs, when used as directed in official labeling, are associated with a risk of causing TdP. Finally, for drugs in class C there is substantial evidence supports their association with a risk of TdP but only under certain conditions (e.g. excessive dose, hypokalemia, congenital long QT or by causing a drug-drug interaction that results in excessive QT interval prolongation) [19].

### Statistical analysis

Our null hypotheses were: 1) no association between the cardiac function monitoring parameters (ECG before AP treatment, ECG during AP treatment, electrolytes levels before AP treatment, electrolytes levels after AP treatment association, personal history of pre-existing cardiac disease) both as single independent dummy variables and as total number of parameters, and the TdP risk category; 2) no association between the cardiac function monitoring parameters (ECG before AP treatment, ECG during AP treatment, electrolytes levels before AP treatment, electrolytes levels after AP treatment association, personal history of pre-existing cardiac disease) both as single independent dummy variables and as total number of parameters, and the AP pharmacological class; 3) no association between the presence of risk factors for QT-related arrhythmias and TdP, such as

---

**Table 1** List of comorbid somatic disorders identified in our systematic chart review

| Cardiac comorbidities               | Congenital and acquired heart conditions |
|-------------------------------------|------------------------------------------|
|                                     | Arrhythmias                              |
|                                     | Previous myocardial infarctions          |
|                                     | Valvular heart diseases                  |
|                                     | Coronary artery diseases                 |
| Vascular comorbidities             | Arterial hypertension                    |
|                                     | Atherosclerotic cardiovascular disease   |
|                                     | Cerebrovascular diseases                 |
|                                     | Aneurisms                                |
|                                     | Chronic venous insufficiency             |
|                                     | Arterial stenosis                        |
| Hematological comorbidities        | Monoclonal gammopathy                    |
|                                     | Lymphomas                                |
| Endocrine comorbidities            | Myelodysplastic syndromes                |
| Gastrointestinal comorbidities     | Hyper/hypothyroidism                     |
|                                     | Hashimoto’s thyroiditis                  |
|                                     | Goiter                                   |
|                                     | Pituitary adenomas                       |
| Infectious disease comorbidities   | Chronic inflammatory bowel diseases      |
|                                     | Gastroesophageal reflux disease          |
|                                     | Peptic ulcer disease                     |
|                                     | Hiatus hernia                            |
|                                     | Celiac disease                           |
| Metabolic comorbidities            | Hepatitis B virus                        |
|                                     | Hepatitis C virus                        |
|                                     | Human immunodeficiency virus             |
| Kidney conditions                  | Carbohydrate intolerance                 |
|                                     | Insulin resistance                       |
|                                     | Diabetes mellitus type I and II          |
|                                     | Hypercholesterolemia                     |
|                                     | Hyperlipidemia                           |
|                                     | Pancreatitis                             |
|                                     | Hyperuricemia                            |
|                                    | Liver diseases                           |
| Neurological comorbidities         | Kidney failure                           |
|                                     | Proteinuria                              |
|                                     | Hematuria                                |
|                                    | Multiple sclerosis                       |
|                                    | Epilepsy                                 |
|                                    | Brain atrophy                            |
|                                    | Autonomic disturbances in the limbs      |
|                                    | Arnold-Chiari syndrome                   |
|                                    | Parkinson’s disease                      |

**Table 1** List of comorbid somatic disorders identified in our systematic chart review (Continued)

| Rheumatic diseases                  | Rheumatoid arthritis and seronegative arthritis, Fibromyalgia, Osteoporosis, Sjögren syndrome, Systemic lupus erythematosus, Respiratory problems |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Miscellaneous comorbid diseases    | Alterations of hemostasis, Skin diseases, Allergies, Diseases of the musculoskeletal system, Cancer and organ hyperplasia, Chromosomal syndromes, Nephrolithiasis |

---

Manchia et al. BMC Psychiatry (2017) 17:121
cardiac or vascular comorbidities, and the choice of AP, or other psychotropic treatment such as antidepressants or mood stabilizers, with low risk for QT prolongation, or the choice of a specific AP pharmacological class. To this end, we studied continuous and categorical clinical variables using univariate analysis (t test or contingency tables as appropriate). When one or more cells had expected values of 5 or less Fisher’s exact test was used in 2 × 2 contingency tables and bootstrap with 1000 samples in larger tables. Non-parametric tests were used when data violated the assumption of normality. We analysed the distributional properties of continuous data assessing normality with the Kolmogorov-Smirnov test. The variables that showed a significant association with the outcome of interest (TdP risk category or AP pharmacological class) were subsequently included into a multinomial or binary logistic regression model, as appropriate, to correct for age and gender. Specifically, binary logistic regression was used when the dependent variable had two possible discrete outcomes. Instead, we used multinomial logistic regression analysis in the case of a dependent variable with more than two possible discrete outcomes, such as the TdP category. Statistical significance was set at \( \alpha = 0.05 \). Our sample had more than 90% of statistical power to detect an effect size \( \omega = 0.5 \) considering an \( \alpha = 0.05 \) and degrees of freedom (df) = 6. All statistical analyses were carried out with IBM® SPSS® Statistics version 22.0.0.0 (64 bit), with the exception of power analysis which was performed with G*Power (Version 3.1.9.2).

**Results**

**Sample characteristics**
The sample was comprised of 434 SMI patients with a mean age of 49.1 ± 14.7 years. The mean age of onset was 30.1 ± 16.1 years with 218 (50.2%) women. The majority of patients (85.5%) had illness duration longer than 3 years. One hundred eighty-eight (43.3%) patients were diagnosed with psychotic disorder, 231 (53.2%) had a mood disorder, and 15 (3.5%) had a PD. One hundred forty-eight (34.1%) patients had a secondary psychiatric diagnosis. Concerning the pattern of comorbidities, 217 (50.0%) had comorbid somatic illnesses, 20 (4.6%) had cardiac conditions, and 49 (11.3%) had vascular diseases. The sample characteristics are detailed in Table 2.

**Association between cardiac function parameters and TdP risk category**
A total of 1348 longitudinal data points on AP treatments were extracted. Each patient received on average 3.1 ± 4.2 AP treatments over the reference period. We first examined each cardiac function parameter with respect to the TdP risk category. Electrolyte and ECG testing baseline were significantly more frequent for AP with known risk of inducing TdP (Category A) and for AP with drugs with possible risk of inducing TdP (Category B) compared to the Category C (both \( p = 0.002 \), Table 3). These associations remained significant when we corrected for age and gender in the multinomial logistic analysis, with higher rates of baseline electrolytes testing in Category A AP (\( p = 0.006 \), OR = 0.1) and Category B (\( p = 0.02 \)) compared to category C, as well as a higher rate of baseline ECG testing in Category A AP (\( p = 0.008 \), OR = 0.19). The number of cardiac function parameters tested was not significantly associated with the TdP risk category (\( p = 0.41 \), Table 3).

**Association between cardiac function parameters and AP pharmacological class**
The analysis of each cardiac function parameter with respect to the AP pharmacological class showed a

---

**Table 2** Characteristics of the study sample (\( N = 434 \))

| Variable | Value |
|----------|-------|
| Women, N (%) | 218 (50.2) |
| Age (mean ± SD) | 49.1 ± 14.7 |
| Age of onset (mean ± SD) | 30.1 ± 16.1 |
| Age class, N (%) | |
| ≤ 20 years | 0 (0.0) |
| 21-30 years | 42 (9.7) |
| 31-40 years | 91 (21.0) |
| > 40 years | 301 (69.4) |
| Illness duration >3 years, N (%) | 371 (85.5) |
| Marital status, N (%) | |
| Single | 237 (54.6) |
| Married/Cohabiting | 126 (29.0) |
| Divorced | 40 (9.2) |
| Widowed | 20 (4.6) |
| NA | 11 (2.5) |
| Employment, N (%) | |
| Employed | 106 (24.4) |
| Student | 28 (6.5) |
| Retired | 79 (18.2) |
| Unemployed | 184 (42.4) |
| NA | 37 (8.5) |
| Main psychiatric diagnosis, N (%) | |
| Psychotic disorder | 188 (43.3) |
| Mood disorder | 231 (53.2) |
| Personality disorder | 15 (3.5) |
| Presence of secondary psychiatric diagnosis, N (%) | 148 (34.1) |
| Presence of comorbid somatic illnesses, N (%) | 217 (50.0) |
| Presence of cardiac comorbidities*, N (%) | 20 (4.6) |
| Presence of vascular comorbidities, N (%) | 49 (11.3) |

SD standard deviation
NA not available
*2 missing data
higher rate of ECG and electrolyte testing during treatment with second generation AP ($p = 0.01$ and $p = 0.02$, respectively) (Table 4). These associations remained significant in the logistic regression model correcting for age and gender ($p = 0.008$, OR = 1.4 and $p = 0.014$, OR = 1.4, respectively). We also found a trend for association between the number of cardiac function parameters tested and the pharmacological class of AP (Table 4). Specifically, the higher the number of parameters tested (from 3 to 5), the higher the frequency of testing in second generation compared to first generation AP.

**Impact of the presence of risk factors for QT-related arrhythmias and TdP on the choice of AP in terms of TdP risk category or pharmacological class**

We found that the choice of AP Category C (i.e. drugs with conditional risk of TdP), was significantly overrepresented compared to the other two categories when individual risk factors for QT-related arrhythmias, such as...

### Table 3 Association between cardiac function parameters and Torsades de Point (TdP) risk category of antipsychotics

| Monitoring parameters                              | AP Torsades de Point risk category, N (%) | $\chi^2$ | P-value |
|----------------------------------------------------|------------------------------------------|---------|---------|
|                                                    | A                          | B        | C        |        |
| Presence of ECG testing before AP treatment        | 49 (29.6)                  | 229 (20.0) | 3 (1.1) | 12.9   | 0.002  |
| Presence of ECG testing during AP treatment        | 46 (28.4)                  | 375 (32.8) | 16 (38.1)| 1.9    | 0.3    |
| Presence of electrolytes levels before AP treatment| 47 (29.0)                  | 246 (21.5) | 2 (4.8) | 12.1   | 0.002  |
| Presence of electrolytes levels during AP treatment| 51 (31.5)                  | 358 (31.3) | 18 (42.9)| 2.5    | 0.3    |
| Presence of personal history of pre-existing cardiac disease | 5 (3.1)  | 57 (5.0)   | 4 (9.5)  | 3.1    | 0.2    |

Number of cardiac function parameters tested

|                  | 0                          | 1                          | 2                          | 3                          | 4                          | 5                          |
|------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Presence of ECG testing before AP treatment        | 63 (38.9)                  | 27 (16.7)                  | 55 (34.0)                  | 8 (4.9)                     | 9 (5.6)                     | 0 (0.0)                     |
| Presence of ECG testing during AP treatment        | 519 (45.4)                 | 190 (16.6)                 | 298 (26.0)                 | 73 (6.4)                    | 56 (4.9)                    | 8 (0.0)                     |
| Presence of electrolytes levels before AP treatment| 20 (47.6)                  | 5 (11.9)                   | 13 (31.0)                  | 4 (9.5)                     | 0 (0.0)                     | 0 (0.0)                     |

**Category A**: drugs with known risk of inducing TdP  
**Category B**: drugs with possible risk of inducing TdP  
**Category C**: drugs with conditional risk of TdP  
AP antipsychotic  
ECG electrocardiogram  
$\chi^2$ 1000 sample bootstrap

### Table 4 Association between cardiac function parameters and pharmacological class of antipsychotics

| Monitoring parameters                              | Pharmacological class of antipsychotics | $\chi^2$ | P-value |
|----------------------------------------------------|-----------------------------------------|---------|---------|
|                                                    | First generation                        | Second generation |       |
| Presence of ECG testing before AP treatment        | 80 (21.5)                  | 200 (20.5) | 0.2    | 0.7    |
| Presence of ECG testing during AP treatment        | 101 (27.2)                 | 336 (34.4) | 6.5    | 0.01   |
| Presence of electrolytes levels before AP treatment| 81 (21.8)                  | 214 (21.9) | 0.004  | 1      |
| Presence of electrolytes levels during AP treatment| 100 (26.9)                 | 327 (33.5) | 5.5    | 0.02   |
| Presence of personal history of pre-existing cardiac disease | 26 (7.0)    | 40 (4.1)   | 4.8    | 0.03   |

Number of cardiac function parameters tested

|                  | 0                          | 1                          | 2                          | 3                          |
|------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Presence of ECG testing before AP treatment        | 165 (44.4)                 | 70 (18.8)                  | 108 (29.0)                 | 14 (3.8)                    |
| Presence of ECG testing during AP treatment        | 437 (44.8)                 | 152 (15.6)                 | 258 (26.4)                 | 71 (7.3)                    |

$\chi^2$ 1000 sample bootstrap
as comorbid somatic illnesses, cardiac comorbidities and vascular comorbidities were present (Table 5). These associations remained significant when correcting for age and gender, with a higher rate of use of TdP risk category C AP when cardiac comorbidities ($p = 0.04$, OR = 0.2), and vascular comorbidities ($p = 0.004$, OR = 0.2) were present. Use of pharmacological treatments determining QT prolongation during AP therapy was significantly underrepresented in TdP risk category A and B AP compared to the category C ($p = 0.003$), a finding that remained significant when correcting for age and gender ($p = 0.039$, OR = 8.45 for TdP Category A and $p = 0.015$, OR = 11.7 for TdP Category B). No association of individual risk factors for the development of QT-related arrhythmias and TdP was found with the AP pharmacological class (Table 6). Use of pharmacological treatments determining QT prolongation during AP therapy was significantly underrepresented in first generation AP compared to second generation AP ($p = 0.001$, Table 6). This finding remained significant when correcting for age and gender in the binary logistic regression model ($p = 0.001$, OR = 0.6).

**Discussion**

The excess morbidity and mortality observed in SMI patients is partly determined by clinical, health system-related, and treatment factors that are modifiable, provided that adequate measures for longitudinal monitoring are undertaken. In our retrospective assessment of 434 SMI patients, we found that psychiatrists performed ECG and electrolyte testing before starting AP treatment on the basis of the risk carried by AP of determining QT prolongation and TdP, but not on the basis of AP pharmacological class. However, second generation AP were more frequently monitored than first generation AP, in terms both of ECG and electrolyte balance, during the course of treatment. Of interest, baseline assessment of risk factors for QT-related arrhythmias and TdP had an effect on the choice of AP treatment leading to the use of drugs with a relatively low TdP risk. This resulted also in a specific prescribing pattern of concomitant treatments increasing the likelihood of QT prolongation during AP therapy, which was higher for Category C AP compared to the other two categories.

Several of these results deserve a comment. Our finding that baseline ECG and electrolyte testing was more frequent with AP at higher risk for QT-related arrhythmias and TdP is consistent with evidence based recommendations that baseline testing of SMI patients can reduce the risk of cardiac events over the course of AP treatment [11, 22]. However, longitudinal cardiac function monitoring was not regularly performed over the course of the reference period for any of the three TdP risk category AP. Several reasons might explain this observation. First, the negative symptomatological core of SMI, particularly SCZ and BD, might determine lack of drive and decreased energy levels that can reduce help-seeking and physical health check-ups [23]. Second, it is plausible that the lack of insight into their mental and physical health condition, as well as the presence of thought disorder such as delusion of control and paranoid/persecutory delusions, can explain the resistance of SMI patients to perform longitudinal periodic testing. Finally, the cognitive decline observed in SMI patient might also influence the lack of adherence to cardiac function monitoring. On the other hand, ECG and electrolyte testing during the reference period were more frequently performed in second generation than in first generation AP. This observation might derive from two factors. First, psychiatrists might be more aware of the effects of second generation AP on QT-related prolongation compared to first generation AP given that the former were more recently introduced into the market. Moreover, second generation AP might have higher rate of prescription given the more favorable side effect profile compared to first generation AP [24].

| Table 5 | Association between individual risk factors for QT-related arrhythmias and Torsades de Pointes (TdP), and TdP risk category of antipsychotics |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Factor                          | AP | Torsades de Point risk category, n (%) | C | $\chi^2$ | P-value |
| Presence of comorbid somatic illnesses | 82 (50.6) | 556 (48.6) | 29 (69.0) | 6.9 | 0.03 |
| Presence of cardiac comorbidities   | 2 (1.2) | 45 (3.9) | 4 (9.5) | 6.8a | 0.03 |
| Presence of vascular comorbidities   | 10 (6.2) | 123 (10.8) | 11 (26.2) | 14.0 | 0.01 |
| Use of pharmacological treatments determining QT prolongation during AP therapy | 134 (82.7) | 885 (77.4) | 41 (97.6) | 11.6 | 0.003 |

Category A: drugs with known risk of inducing TdP
Category B: drugs with possible risk of inducing TdP
Category C: drugs with conditional risk of TdP
AP antipsychotic
*a $\chi^2$1000 sample bootstrap
Another interesting finding was that psychiatrists of our community health center prescribed AP at low risk of inducing TdP (Category C) when individual risk factors for QT-related arrhythmias were present. This result is consistent with evidence-based recommendations indicating that baseline screening for cardiovascular risk factors should be performed in order to facilitate targeted treatment-decision making [11]. Of importance, we also identified specific prescribing patterns where AP at low risk of inducing TdP (Category C) resulted more frequently associated with concomitant treatments at increased risk of QT-related arrhythmias. This finding is of particular importance given that TdP might result from additive effect of drugs on cardiac ion channels and might also derive from pharmacokinetic interactions increasing the bioavailability of the interacting drugs [14].

Our results should be interpreted in the context of some limitations. First, the retrospective nature of our study did not permit to assess the temporal relationship between cardiac function testing and the beginning of AP treatment. However, our data were based on accurate and detailed longitudinally collected clinical information. Second, our sample population attended a community mental health center and consequently our results might lack generalizability and be susceptible to selection bias. Third, we could not test for the effect of psychiatry training on clinical monitoring as well as treatment decision-making. It is conceivable that more senior psychiatrists could have higher awareness of the need of performing ECG and biochemical testing in AP treated SMI patients, as well as be more knowledgeable about the side effect profiles of the psychotropic treatment. Interestingly, a survey of junior psychiatrists’ knowledge of ECG monitoring appears to support the latter hypothesis [25]. Fourth, our sample size, although not negligible, might have not been adequately powered to identify pattern of associations with small to moderate magnitude of effect size as shown by our power analysis. Fifth, our findings might have been affected by the lack of stability in longitudinal clinical assessments and data collection. Finally, we limited our reference period to five years. An extension of the reference period for the retrospective assessment, as well as the use of a prospective design, could lead to the identification of some of the obstacles hindering the implementation of evidence-based recommendations for cardiac function monitoring in AP-treated SMI patients.

### Conclusions

Our retrospective study led to the identification of weaknesses in the adherence to cardiac function monitoring guidelines in SMI patients treated with AP in real life clinical practice. Our results appear concordant with previous research showing that clinicians tend to perform poorly at monitoring cardiovascular health in this patient population [26–28]. Indeed, Roberts et al. found that SCZ patients were half as likely as asthma controls to have blood pressure and cholesterol levels recorded [26]. Patients with SMI over 60 years of age were less likely to receive annual cardiovascular screening than the general population despite higher risk of developing cardiovascular diseases [27]. And cardiovascular monitoring appeared to be poor even in SCZ patients treated with clozapine, which is associated with potentially life-threatening cardiac conditions [28].

In conclusion, our study highlights the need for the development of specific educational programs to facilitate the application of adequate cardiovascular monitoring in clinical setting. These programs should focus on increasing the knowledge on the safety profile of AP with the aim of developing TdP class-specific monitoring guidelines. A more pragmatic approach toward cardiovascular function monitoring of SMI patients should also be based on a closer interaction with general practitioners. Should these health policies be implemented thoroughly, the care, and the quality of life, of SMI patients will improve substantially.

### Acknowledgements

We wish to thank the clinical staff, the nurses and residents at the Section of Psychiatry of the University of Cagliari for the constant commitment to the care of mental health patients.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

---

**Table 6** Association between individual risk factors for QT-related arrhythmias and TdP, and pharmacological class of antipsychotics

| Factor                        | Pharmacological class of antipsychotics | χ² | P-value |
|-------------------------------|----------------------------------------|----|---------|
| Presence of comorbid somatic illnesses | First generation | 191 (51.3) | 0.7 | 0.4 |
| Presence of cardiac comorbidities | Second generation | 476 (48.8) | 0.9 | 0.35 |
| Presence of vascular comorbidities | First generation | 17 (4.6) | 0.3 | 0.6 |
| Presence of cardiac comorbidities | Second generation | 34 (3.5) | 0.3 | 0.6 |
| Presence of vascular comorbidities | First generation | 37 (9.9) | 0.3 | 0.6 |
| Presence of cardiac comorbidities | Second generation | 107 (11.0) | 0.3 | 0.6 |
| Presence of vascular comorbidities | First generation | 17 (4.6) | 0.3 | 0.6 |
| Presence of cardiac comorbidities | Second generation | 34 (3.5) | 0.3 | 0.6 |
| Presence of vascular comorbidities | First generation | 37 (9.9) | 0.3 | 0.6 |
| Presence of cardiac comorbidities | Second generation | 107 (11.0) | 0.3 | 0.6 |

AP antipsychotic
ECG electrocardiogram

In this patient population [26–28]. Indeed, Roberts et al. found that SCZ patients were half as likely as asthma controls to have blood pressure and cholesterol levels recorded [26]. Patients with SMI over 60 years of age were less likely to receive annual cardiovascular screening than the general population despite higher risk of developing cardiovascular diseases [27]. And cardiovascular monitoring appeared to be poor even in SCZ patients treated with clozapine, which is associated with potentially life-threatening cardiac conditions [28].

In conclusion, our study highlights the need for the development of specific educational programs to facilitate the application of adequate cardiovascular monitoring in clinical setting. These programs should focus on increasing the knowledge on the safety profile of AP with the aim of developing TdP class-specific monitoring guidelines. A more pragmatic approach toward cardiovascular function monitoring of SMI patients should also be based on a closer interaction with general practitioners. Should these health policies be implemented thoroughly, the care, and the quality of life, of SMI patients will improve substantially.

### Acknowledgements

We wish to thank the clinical staff, the nurses and residents at the Section of Psychiatry of the University of Cagliari for the constant commitment to the care of mental health patients.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Availability of data and materials
For access to the data in this paper, interested researchers may contact the corresponding author via email: mirkomanchia@unicait.

Authors’ contributions
MMI drafted the first version of the manuscript, and performed data analysis. GF collected clinical data and wrote part of the manuscript. BC conceptualized and supervised the work, and wrote part of the manuscript. FP conceptualized the study, supervised the work, and wrote part of the manuscript. All authors read and approved the final version of the manuscript.

Competing interests
The authors declare that there is no conflict of interest. The authors alone are responsible for the content and writing of the paper.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The Ethics Committee of the University Hospital Agency, University of Cagliari reviewed the project description and concluded that it did not require ethical evaluation as it was a reanalysis of data collected in clinical settings. All patients gave written consent to the use of clinical data for research purposes.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 27 August 2016 Accepted: 27 March 2017
Published online: 31 March 2017

References
1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
2. De Hert M, Corell CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52-77.
3. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in patients with schizophrenia. JAMA Psychiatry. 2014;71:1533-60.
4. Nordentoft M, Wahlbeck K, Hallgren J, Westman J, Oxby U, Alinaghizadeh H, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8:e55176.
5. Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care. 2011;49:599-604.
6. Corell CU, Detrau J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119-36.
7. Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, et al. Atrisk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011;70:59-63.
8. Kooy FH. Hyperglycaemia in mental disorders. Brain. 1979;4:214-8.
9. Raphael T, Parsons JP. Blood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatr. 1921;5:687-709.
10. Ammann-Zakenstein D, Avidan N, Kanyas K, Ebstein RP, Kohn Y, Hamdan A, et al. AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. Eur J Hum Genet. 2006;14:1111-9.
11. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetis DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines; plus recommendations at the system and individual level. World Psychiatry. 2011;10:138-51.
12. Brunton L, Chabner BA, Knollmann BC. Goodman and Gilman’s the pharmacological basis of Therapeutics. Twelfth ed. New York (NY): McGraw-Hill; 2011.
13. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: amultitude-treatments meta-analysis. Lancet. 2013;382:951-62.
14. Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de points, and sudden death. Am J Psychiatry. 2001;158:1774-82.
15. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 2000;25:154-60.
16. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 1998;286:788-93.
17. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol. 1997;120:968-74.
18. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia. Second edition. Am J Psychiatry. 2004;161:1-56.
19. Wootsey RL, Romero KA: http://www.crediblemeds.org/, QTdrug List. AZCERT, Inc 2015; 1822 Innovation Park Dr., Oro Valley, AZ 85755.
20. NICE. Psychosis and schizophrenia in adults: prevention and management. https://www.nice.org.uk/guidance/cg178. 2014.
21. American Psychiatric Association: American Psychiatric Association: diagnostic and statistical manual of mental disorders (4th ed., text rev.). 1st edn. Washington, DC: American Psychiatric Association; 2000.
22. Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics part 2: monitoring and prevention. Adv Psychiatr Treat. 2006;12:100-9.
23. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116:317-33.
24. Awad AG, Vonuganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877-93.
25. Darwiche FZ, Ugradar ST, Turner T. Junior doctors’ knowledge and practice of electrocardiographic monitoring for high-risk patients receiving antipsychotic medications. Psychiatr Bull. 2009;33:377-80.
26. Roberts L, Roalle A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract. 2007;24:34-40.
27. Osborn DP, Baio G, Walters K, Petersen I, Limburg H, Raine R, et al. Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care: cohort study in the United Kingdom THIN primary care database 2000-2007. Schizophr Res. 2011;129:104-10.
28. Jones WR, Narayana U, Howarth S, Shinners J, Nazaar Q. Cardiovascular monitoring in patients prescribed clozapine. Psychiatr Bull (2014). 2014;38:140.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit